Survodutide

Survodutide (BI 456906 / Dual GLP-1 & Glucagon Receptor Agonist)

Description:
Survodutide is a long-acting dual agonist peptide that targets both the GLP-1 (glucagon-like peptide-1) and glucagon (GCGR) receptors. It is designed to combine the appetite-suppressing and glucose-regulating properties of GLP-1 activation with the energy-expending and lipolytic effects of glucagon signaling. Survodutide is currently under investigation for its potential to promote weight reduction, metabolic optimization, and liver fat clearance, while maintaining glycemic balance.

Key Benefits:

• Dual GLP-1 / glucagon receptor activation for enhanced metabolic effects

• Promotes significant fat loss and appetite regulation in preclinical studies

• Increases energy expenditure and supports hepatic lipid metabolism

• Improves glycemic control and insulin sensitivity

• Supports research on obesity, MASH, and metabolic disease mechanisms

Mechanism of Action:
Survodutide mimics oxyntomodulin, a natural gut hormone with balanced activity on both GLP-1 and glucagon receptors. Through GLP-1 receptor activation, it enhances insulin secretion, slows gastric emptying, and suppresses appetite. Concurrent glucagon receptor activation stimulates lipolysis, fat oxidation, and energy expenditure. Together, these effects create a synergistic dual-pathway mechanism promoting sustained fat loss and improved metabolic homeostasis without excessive hyperglycemia.

Molecular Type: Dual receptor agonist peptide (GLP-1R/GCGR)
Synonyms: BI 456906
Molecular Weight: Variable (modified peptide, albumin-binding conjugate)
Form: Lyophilized powder for reconstitution or sterile solution (research grade)
Purity: ≥98% (HPLC)

Storage:
Store at −20 °C. Protect from light, heat, and moisture. Once reconstituted, refrigerate (2–8 °C) and use within 30 days. Avoid repeated freeze–thaw cycles.

Disclaimer:
For laboratory research use only. Not for human consumption.